Navigation Links
New One-Year Pharmacoeconomic Study Shows Avonex is Cost-Effective,Relative to Other Interferon Therapies for Multiple Sclerosis

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 13, 2007 - Biogen Idec Inc. (NASDAQ: BIIB) announced today that one-year data presented at the Academy of Managed Care Pharmacy's (AMCP) 2007 Annual Meeting show that AVONEX(R) (Interferon beta-1a) is a cost-effective therapy in multiple sclerosis (MS) when compared to other interferon beta treatments. Using a comprehensive analysis of medical and pharmacy costs, the results of the research concluded that patients treated with AVONEX, the most prescribed MS therapy worldwide, have the lowest total one-year cost to a health plan when compared to other interferon beta treatments.

Researchers analyzed 10,622 patients over one year to assess how demographic, administrative and clinical variables affect MS costs and utilization patterns and to examine the economic impact of treating MS. The independent data contained in Multiple Sclerosis Benchmarks(TM)(1), the retrospective, claims-based, observational study, showed that patients treated with AVONEX had the lowest average one-year cost compared to patients receiving other interferon beta treatments. It has been estimated that the total annual economic burden of MS in the United States exceeds $6.8 billion with a lifetime cost of $2.2 million per patient.(2)

"MS is a disease that can have an impact beyond its debilitating effect on patients," said Michael Pollock, Vice President, Global Health Economics, Biogen Idec. "Cost-effectiveness is an increasingly important factor in treating chronic diseases like MS. This study shows that in addition to its clinical impact, AVONEX can also help to substantially reduce the cost of care for patients living with this disease, when compared to other interferon beta treatments."

The MS Benchmarks analysis showed the total costs over one-year to MS patients on interferon beta therapy were: AVONEX, $19,896.15; Rebif(R) (Interferon beta-1a) sc, $22,207.85; and Betaseron(R) (Inter
'"/>




Page: 1 2 3

Related medicine technology :

1. Acuity One-Year Findings Meet All Primary Endpoints in Favor of Angiomax (Bivalirudin) Alone Treatment Group
2. First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone Was More Cost-Effective Than Interferon Beta Therapies for Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
5. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
Post Your Comments:
(Date:3/27/2015)... Dynatronics Corporation (NASDAQ: DYNT ) today announced ... the Company,s Board of Directors effective March 23, 2015, to ... of board member Joseph Barton .  ... of Directors represents an important step forward for the company," ... Dynatronics.  "Rich is a proven leader and is well-known for ...
(Date:3/27/2015)... March 27, 2015 Biopharmaceutical Industry Leads ... industry comes out on top as the country,s manufacturing ... new report  from ndp│analytics. According to the  analysis , ... investment over the last decade, accounting for 27 percent ... A Short Video on Medicare Part D ...
(Date:3/27/2015)... 2015   Cypher Genomics, Inc., the ... showing that, compared to a panel of experts, ... equivalent interpretations of whether certain genetic abnormalities were ... a fraction of the time. Cypher,s Mantis software ... genetic analysis in non-invasive prenatal testing (NIPT) by ...
Breaking Medicine Technology:Dynatronics Announces Appointment of Richard J. Linder to Board of Directors 2Week in Review: The Latest from PhRMA 2New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 2New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 3
... Inc. (Nasdaq: CEPH ) today announced that ... antiepileptic medication GABITRIL(R) (tiagabine hydrochloride) has been approved by ... REMS consists of a Medication Guide to inform patients ... GABITRIL.  The implementation of the REMS is a result ...
... N.J., Oct. 14 PDR Network, already the ... Alerts to U.S. prescribers, announced that this month ... Risk Evaluation and Mitigation Strategies ("REMS") program alerts ... electronically to prescribers by PDR Network,s Health Care ...
Cached Medicine Technology:Cephalon Announces FDA Approval of a Risk Evaluation and Mitigation Strategy for GABITRIL 2Cephalon Announces FDA Approval of a Risk Evaluation and Mitigation Strategy for GABITRIL 3Cephalon Announces FDA Approval of a Risk Evaluation and Mitigation Strategy for GABITRIL 4PDR Network Delivers Six Million Drug Alerts & REMS 2PDR Network Delivers Six Million Drug Alerts & REMS 3
(Date:3/27/2015)... 2015 Bleeding is one of ... coronary intervention (PCI), resulting in increased mortality, morbidity, ... paradox,” in which the highest-risk PCI patients with ... less often with bleeding avoidance strategies than lower-risk ... America Heart Institute asked the question whether prospectively ...
(Date:3/27/2015)... CA (PRWEB) March 27, 2015 Healthpointe ... Stanley G. Katz, M.D., is now treating knee and ... including Anaheim , Long Beach, and La Mirada. ... of acute knee and hip joint disorders as well ... Katz is passionate in returning his patients back to ...
(Date:3/27/2015)... Ticket Down is a reputable source for authentic tickets ... a phenomenal and highly successful live tour last year, the cast ... tour again in 2015 and they will be visiting 8 cities ... in New York City at the cozy Beacon Theatre and will ... 10th. , Fans of the hit show can look forward to ...
(Date:3/27/2015)... While deep learning was the topic of many ... , the CEO of one start-up spoke passionately about using ... well beyond the generally-agreed ceiling of 120 years. , Insilico ... of 12 companies recognized as the hottest GPU-powered startups in ... GTC Emerging Companies Summit have business models focused on ...
(Date:3/27/2015)... 2015 According to a recently published ... plate and screw market in Europe is in decline ... and screw segment. Price decreases are being seen across ... 50% of the total European trauma device market, continued ... market value, year after year. , “Such price ...
Breaking Medicine News(10 mins):Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 2Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 3Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 2Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 3Health News:Nashville Live in Concert Tickets in New York, Boston, Washington, DC, Chicago, Minneapolis, San Francisco, Los Angeles and Phoenix Now On Sale at TicketDown.com 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 3Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 3
... Demand Continues for Ozone Laundry and Energy Efficient Lighting Upgrades ... ... TOWNSHIP, N.J., Oct. 9 National,Energy Services Company, Inc. (OTC Bulletin Board: ... System (OLS) and,Energy Efficient Lighting Upgrades. Golden Living skilled nursing,facilities in Indiana ...
... and essential for trials that are investigating treatments for ... the European Medical Research Councils (EMRC), the membership organisation ... European Science Foundation (ESF) in Strasbourg, which is coordinating ... a review of how best to implement clinical trials ...
... new report from the National Research Council recommends that ... into risk assessments of chemicals and medicines, and calls ... potential to protect public health. Chemicals and drugs ... other cell activity, and research on these processes -- ...
... is Sixth Location for Miami Beach Community Health Center, ... location of,the Miami Beach Community Health Center (MBCHC) is ... 11th from noon to 2 p.m. The,full-service medical clinic, ... Services (CHS), is the sixth location for MBCHC, which,runs ...
... a,long time to develop, which suggests that it may ... disease process, to delay the start of,symptoms. Over the ... "disease-modifying" drugs that target the earliest biological changes,in Alzheimer,s, ... Health,Letter., None of the disease-modifying drugs now in ...
... The U.S. Government,through the U.S. Agency for ... receive grants under the Malaria,Communities Program (MCP). These ... to help extend the coverage of malaria prevention ... with specific,attention on children under age five and ...
Cached Medicine News:Health News:National Energy Services Receives Repeat Orders From Golden Living and Cathedral Rock Skilled Nursing Facilities 2Health News:Paving the way for future pan-European clinical trials 2Health News:Paving the way for future pan-European clinical trials 3Health News:Genomic technologies to identify toxic chemicals should be developed 2Health News:Genomic technologies to identify toxic chemicals should be developed 3Health News:New Medical Clinic at Center for Haitian Studies to Host Open House on October 11th 2Health News:Cautious Optimism for New Alzheimer's Medications, Reports the Harvard Mental Health Letter 2Health News:USAID Announces First Malaria Communities Program Grants 2
Constructed from soft Shur-grip foam and velcro closure for easy application and - reapplication...
... Cobalt Binding (ACB®) Test is a clinical ... (IMA®) by measuring the cobalt binding capacity ... First identified in the early 1990s, IMA ... contact with ischemic tissue in the heart. ...
... Albumin Cobalt Binding (ACB®) Test is a ... Albumin (IMA®) by measuring the cobalt binding ... sample. First identified in the early 1990s, ... in contact with ischemic tissue in the ...
Our Osteomark® ELISA kits provide a quantitative measurement of cross-linked N-telopeptides of type I collagen (NTx) as an indicator of bone resorption, with higher levels in serum or urine sampl...
Medicine Products: